These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19301121)

  • 21. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms].
    Grell P; Svoboda M; Simícková M; Fabian P; Vyzula R
    Klin Onkol; 2009; 22(2):45-51. PubMed ID: 19522373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
    du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.
    Lenz G; Hamilton A; Geng S; Hong T; Kalkum M; Momand J; Kane SE; Huss JM
    Clin Cancer Res; 2018 Mar; 24(5):1216-1226. PubMed ID: 29180608
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
    Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
    Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
    Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
    Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
    Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
    Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
    Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
    Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and validation of an ERBB2 gene expression signature in breast cancers.
    Bertucci F; Borie N; Ginestier C; Groulet A; Charafe-Jauffret E; Adélaïde J; Geneix J; Bachelart L; Finetti P; Koki A; Hermitte F; Hassoun J; Debono S; Viens P; Fert V; Jacquemier J; Birnbaum D
    Oncogene; 2004 Apr; 23(14):2564-75. PubMed ID: 14743203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.
    Rennstam K; Jönsson G; Tanner M; Bendahl PO; Staaf J; Kapanen AI; Karhu R; Baldetorp B; Borg A; Isola J
    Cancer Genet Cytogenet; 2007 Jan; 172(2):95-106. PubMed ID: 17213017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
    Ross JS
    Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells.
    Murad R; Avanes A; Ma X; Geng S; Mortazavi A; Momand J
    Gene; 2021 Oct; 799():145808. PubMed ID: 34224831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
    Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERBB2 amplifications in esophageal adenocarcinoma.
    Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
    Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to trastuzumab: a necessary evil or a temporary challenge?
    Cardoso F; Piccart MJ; Durbecq V; Di Leo A
    Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.